Your session is about to expire
← Back to Search
Sacituzumab Govitecan-hziy for Metastatic Cancer
Study Summary
This trial is testing the long-term safety of a drug for people with metastatic solid tumors who are benefiting from the drug.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2020 Phase 3 trial • 529 Patients • NCT02574455Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I stopped taking sacituzumab govitecan-hziy due to severe side effects.I am currently receiving sacituzumab govitecan treatment in a Gilead study.I am not pregnant or breastfeeding.I started a new cancer treatment after my last dose in a previous study.I am currently benefiting from sacituzumab govitecan-hziy treatment.
- Group 1: Sacituzumab Govitecan-hziy
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Drug Has Already Been Approved - The FDA has already approved this drug, and is just seeking more data.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Could you provide me with a synopsis of the prior investigations involving Sacituzumab Govitecan-hiy?
"Sacituzumab Govitecan-hiy was first researched by Comprehensive Cancer Centers of Nevada (CCCN) - Central Valley in 2018. Since then, two clinical trials have been concluded and there are 33 investigations ongoing as of today, with an abundance occuring within the confines of Chicago, Illinois."
What maladies is Sacituzumab Govitecan-hiy ordinarily applied to combat?
"Sacituzumab Govitecan-hiy is a widely used therapeutic procedure, as well as having potential applications in pharmacotherapy and breast cancer."
Are any additional participants being taken on for this trial?
"Unfortunately, no new candidates are being accepted presently. The trial was initially announced on August 4th 2020 and the last update to it occurred on November 7th 2022. If you're seeking additional studies, there are currently 2387 trials recruiting cancer patients and 33 specifically offering Sacituzumab Govitecan-hiy treatment options."
What is the aggregate amount of subjects involved in this experiment?
"At this time, the clinical trial does not have any open recruitment. It was first posted on August 4th 2020 and last updated November 7th 2022. However, there are currently 2387 trials looking for cancer patients and 33 studies searching for participants to receive Sacituzumab Govitecan-hiy as a treatment."
How deleterious is the application of Sacituzumab Govitecan-hiy for individuals?
"There is ample evidence that Sacituzumab Govitecan-hiy has been approved, thus the safety score for this medication was 3."
Is this research endeavor unprecedented in its scope?
"As of now, 33 extant trials involving Sacituzumab Govitecan-hiy are being conducted in 418 cities across 32 nations. The initial trial was sponsored by Hoffmann-La Roche and involved 435 patients; it reached Phase 1 & 2 drug approval status. Since 2018, two further studies have been concluded."
Who else is applying?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger